Swallis Medical obtains CE marking for SWALLIS DSATM (Swallowing Analysis Device), an innovative medical device indicated for the detection and analysis of pharyngo-laryngeal activity.
• SWALLIS DSATM offers a new approach to swallowing assessment for patients at risk of dysphagia (swallowing disorders), a condition that affects up to 75% of stroke patients as well as patients with Parkinson's disease, ALS, the incidence of which increases with age. Half of COVID19 patients who have undergone long intubation also have dysphagia.
• CE marking is an important milestone for upcoming launches in markets around the world.
• SWALLIS DSATM will soon be launched in Europe.
Become a member
Become a member
Member area
Member area
events
events
